Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
BMC Biol ; 22(1): 36, 2024 Feb 14.
Article in English | MEDLINE | ID: mdl-38355543

ABSTRACT

BACKGROUND: The identification of cell type-specific genes and their modification under different conditions is central to our understanding of human health and disease. The stomach, a hollow organ in the upper gastrointestinal tract, provides an acidic environment that contributes to microbial defence and facilitates the activity of secreted digestive enzymes to process food and nutrients into chyme. In contrast to other sections of the gastrointestinal tract, detailed descriptions of cell type gene enrichment profiles in the stomach are absent from the major single-cell sequencing-based atlases. RESULTS: Here, we use an integrative correlation analysis method to predict human stomach cell type transcriptome signatures using unfractionated stomach RNAseq data from 359 individuals. We profile parietal, chief, gastric mucous, gastric enteroendocrine, mitotic, endothelial, fibroblast, macrophage, neutrophil, T-cell, and plasma cells, identifying over 1600 cell type-enriched genes. CONCLUSIONS: We uncover the cell type expression profile of several non-coding genes strongly associated with the progression of gastric cancer and, using a sex-based subset analysis, uncover a panel of male-only chief cell-enriched genes. This study provides a roadmap to further understand human stomach biology.


Subject(s)
Stomach Neoplasms , Transcriptome , Humans , Male , Stomach , Epithelial Cells , Gene Expression Profiling
2.
J Prev Alzheimers Dis ; 10(1): 9-18, 2023.
Article in English | MEDLINE | ID: mdl-36641605

ABSTRACT

BACKGROUND: Consensus is lacking on what constitutes a meaningful score change for individual patients on clinical outcome assessments (COAs) that are commonly used in clinical trials of Alzheimer's disease. Such thresholds are one important approach to help contextualize trial results and demonstrate meaningful treatment benefit. OBJECTIVES: To estimate meaningful within-patient change thresholds for the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog), and the Mini-Mental State Examination (MMSE) among participants with mild cognitive impairment (MCI). DESIGN: Retrospective anchor- and distribution-based analyses of data from the ADC-008 (NCT00000173) study were used to estimate thresholds for meaningful within-patient change on the target measures. SETTING: Analyses were conducted using data from ADC-008 a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study among participants with the amnestic subtype of MCI, which was conducted by the Alzheimer's Disease Cooperative Study (ADCS) between March 1999 and January 2004 in the United States and Canada. PARTICIPANTS: Analyses were based on 769 eligible participants who completed the baseline assessment from 69 ADCS sites in the United States and Canada. MEASUREMENTS: The target outcome measures for this analysis included the CDR-SB, the ADAS-Cog, and the MMSE. The anchor measures for this analysis included the Global Deterioration Scale and the MCI-Clinical Global Impression of Change. RESULTS: Focusing on the 12-month time point, within-patient increases of 1-2.5 points in the CDR-SB and increases of 2-5 points on the 11-item ADAS-Cog and 13-item ADAS-Cog, on average, reflect minimal-to-moderate levels of deterioration, respectively. CONCLUSIONS: These thresholds may be useful to aid the interpretation of Alzheimer's disease clinical trial data by illustrating meaningful within-patient progression over the course of a clinical trial via supplementary progressor analyses, which may in turn be informative for treatment decisions. Estimates generated via these methods are specifically intended to evaluate within-patient change and are not intended to assess the magnitude and meaningfulness of differences between group-level changes over time.


Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Humans , Alzheimer Disease/complications , Alzheimer Disease/diagnosis , Alzheimer Disease/drug therapy , Retrospective Studies , Cognitive Dysfunction/complications , Cognitive Dysfunction/diagnosis , Outcome Assessment, Health Care , Mental Status and Dementia Tests
3.
Cytokine ; 111: 563-566, 2018 11.
Article in English | MEDLINE | ID: mdl-29807687

ABSTRACT

Endothelial cells (EC) are critical sites of human cytomegalovirus (hCMV) infection in vivo. Infection can induce the production of various EC cytokines, such as interleukin (IL-)6, which can have autocrine and/or paracrine effector functions. Here, we report that hCMV induces the production of EC IL-11, a relatively understudied member of the IL-6-type cytokine family. We detail temporal EC IL-11 translation and protein secretion dynamics in response to hCMV infection, and reveal distinct differences compared to EC IL-6. Viral replication had markedly opposing effects on the regulation of these closely related cytokines, representing a major driving force behind IL-11 production, whilst concurrently suppressing IL-6 expression. This is the first report of any biological agent that stimulates EC IL-11 production.


Subject(s)
Cytomegalovirus Infections/metabolism , Cytomegalovirus/genetics , Endothelial Cells/metabolism , Endothelial Cells/virology , Interleukin-11/metabolism , Virus Replication/genetics , Cells, Cultured , Cytokines/metabolism , Cytomegalovirus Infections/virology , Human Umbilical Vein Endothelial Cells , Humans
4.
Ann Oncol ; 29(6): 1468-1475, 2018 06 01.
Article in English | MEDLINE | ID: mdl-29617726

ABSTRACT

Background: There is observational evidence suggesting that high vitamin D concentrations may protect against lung cancer. To investigate this hypothesis in detail, we measured circulating vitamin D concentrations in prediagnostic blood from 20 cohorts participating in the Lung Cancer Cohort Consortium (LC3). Patients and methods: The study included 5313 lung cancer cases and 5313 controls. Blood samples for the cases were collected, on average, 5 years before lung cancer diagnosis. Controls were individually matched to the cases by cohort, sex, age, race/ethnicity, date of blood collection, and smoking status in five categories. Liquid chromatography coupled with tandem mass spectrometry was used to separately analyze 25-hydroxyvitamin D2 [25(OH)D2] and 25-hydroxyvitamin D3 [25(OH)D3] and their concentrations were combined to give an overall measure of 25(OH)D. We used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for 25(OH)D as both continuous and categorical variables. Results: Overall, no apparent association between 25(OH)D and risk of lung cancer was observed (multivariable adjusted OR for a doubling in concentration: 0.98, 95% CI: 0.91, 1.06). Similarly, we found no clear evidence of interaction by cohort, sex, age, smoking status, or histology. Conclusion: This study did not support an association between vitamin D concentrations and lung cancer risk.


Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Non-Small-Cell Lung/epidemiology , Lung Neoplasms/epidemiology , Small Cell Lung Carcinoma/epidemiology , Vitamin D Deficiency/physiopathology , Vitamin D/blood , Adenocarcinoma/blood , Adenocarcinoma/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Large Cell/blood , Carcinoma, Large Cell/epidemiology , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Squamous Cell/blood , Carcinoma, Squamous Cell/epidemiology , Case-Control Studies , Female , Follow-Up Studies , Global Health , Humans , Lung Neoplasms/blood , Male , Middle Aged , Prognosis , Prospective Studies , Risk Factors , Small Cell Lung Carcinoma/blood , Vitamins/blood , Young Adult
5.
Oncogene ; 36(1): 24-34, 2017 01 05.
Article in English | MEDLINE | ID: mdl-27270433

ABSTRACT

MicroRNA-375 (miR-375) is frequently elevated in prostate tumors and cell-free fractions of patient blood, but its role in genesis and progression of prostate cancer is poorly understood. In this study, we demonstrated that miR-375 is inversely correlated with epithelial-mesenchymal transition signatures (EMT) in clinical samples and can drive mesenchymal-epithelial transition (MET) in model systems. Indeed, miR-375 potently inhibited invasion and migration of multiple prostate cancer lines. The transcription factor YAP1 was found to be a direct target of miR-375 in prostate cancer. Knockdown of YAP1 phenocopied miR-375 overexpression, and overexpression of YAP1 rescued anti-invasive effects mediated by miR-375. Furthermore, transcription of the miR-375 gene was shown to be directly repressed by the EMT transcription factor, ZEB1. Analysis of multiple patient cohorts provided evidence for this ZEB1-miR-375-YAP1 regulatory circuit in clinical samples. Despite its anti-invasive and anti-EMT capacities, plasma miR-375 was found to be correlated with circulating tumor cells in men with metastatic disease. Collectively, this study provides new insight into the function of miR-375 in prostate cancer, and more broadly identifies a novel pathway controlling epithelial plasticity and tumor cell invasion in this disease.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Epithelial-Mesenchymal Transition/genetics , Gene Expression Regulation, Neoplastic , MicroRNAs/genetics , Phosphoproteins/genetics , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Signal Transduction , Zinc Finger E-box-Binding Homeobox 1/metabolism , 3' Untranslated Regions , Adaptor Proteins, Signal Transducing/metabolism , Animals , Biomarkers , Cell Line, Tumor , Epithelium/metabolism , Epithelium/pathology , Gene Expression , Humans , Male , Neoplastic Cells, Circulating/metabolism , Neoplastic Cells, Circulating/pathology , Phenotype , Phosphoproteins/metabolism , Prostatic Neoplasms/pathology , Proto-Oncogene Proteins c-met/genetics , Proto-Oncogene Proteins c-met/metabolism , RNA Interference , Transcription Factors , YAP-Signaling Proteins , Zinc Finger E-box-Binding Homeobox 1/genetics
6.
Soc Sci Med ; 166: 169-176, 2016 10.
Article in English | MEDLINE | ID: mdl-27566046

ABSTRACT

INTRODUCTION: HIV prevention interventions targeting couples are efficacious, cost-effective and a key strategy for preventing HIV transmission. Awareness of the full spectrum of relationship types and underlying complexities, as well as available support mechanisms in a given context, are critical to the design of effective couple-based interventions. OBJECTIVE: This paper is based on a sub-analysis of a qualitative research study investigating HIV disclosure dynamics amongst pregnant women living with HIV in Durban, South Africa. The sub-analysis explored the nature of participants' social and relationship contexts and consequences of these dynamics on women's feelings of trust towards partners and perceptions of partner commitment. METHODS: Between June and August 2008, we conducted in-depth interviews with 62 pregnant women living with HIV and accessing Prevention of Mother-to-Child Transmission (PMTCT) services in Durban, South Africa. Transcripts were coded for emergent themes and categories using a grounded theoretical approach. RESULTS: The median age of participants was 26 years (interquartile range: 22-29 years). Three major themes with accompanying sub themes were identified: 1) relationship types (sub themes included unmarried status, minimal cohabitation with partners, presence of concurrent relationships), 2) relationship quality/functioning (sub themes included low trust and expectation of partner commitment, relationship turbulence, and lack of communication/ability to negotiate protective behaviours), and 3) factors underlying the relationship functioning (sub themes included dynamics of concurrent relationships coinciding with concurrent pregnancies, gender roles and unequal relationship power, intimate partner violence or threat thereof, and lack of social support). CONCLUSIONS: Our research findings indicate a lack of many of the dyadic relationship elements underlying couple-counselling frameworks for successful risk reduction coordination. Understanding sexual behaviour and the accompanying relationship dynamics within different types of partnerships is crucial for the optimal design of couple-based HIV prevention interventions.


Subject(s)
HIV Infections/prevention & control , Interpersonal Relations , Sexual Behavior/psychology , Sexual Partners/psychology , Adult , Female , HIV Infections/psychology , HIV Infections/transmission , Humans , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy , Pregnant Women/psychology , Qualitative Research , Social Support , South Africa
7.
Thromb Haemost ; 112(2): 332-41, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24816772

ABSTRACT

Low-density lipoproteins (LDL), occurring in vivo in both their native and oxidative form, modulate platelet function and thereby contribute to atherothrombosis. We recently identified and demonstrated that 'ApoB100 danger-associated signal 1' (ApoBDS-1), a native peptide derived from Apolipoprotein B-100 (ApoB100) of LDL, induces inflammatory responses in innate immune cells. Platelets are critically involved in the development as well as in the lethal consequences of atherothrombotic diseases, but whether ApoBDS-1 has also an impact on platelet function is unknown. In this study we examined the effect of ApoBDS-1 on human platelet function and platelet-leukocyte interactions in vitro. Stimulation with ApoBDS-1 induced platelet activation, degranulation, adhesion and release of proinflammatory cytokines. ApoBDS-1-stimulated platelets triggered innate immune responses by augmenting leukocyte activation, adhesion and transmigration to/through activated HUVEC monolayers, under flow conditions. These platelet-activating effects were sequence-specific, and stimulation of platelets with ApoBDS-1 activated intracellular signalling pathways, including Ca2+, PI3K/Akt, PLC, and p38- and ERK-MAPK. Moreover, our data indicates that ApoBDS-1-induced platelet activation is partially dependent of positive feedback from ADP on P2Y1 and P2Y12, and TxA2. In conclusion, we demonstrate that ApoBDS-1 is an effective platelet agonist, boosting platelet-leukocyte's proinflammatory responses, and potentially contributing to the multifaceted inflammatory-promoting effects of LDL in the pathogenesis of atherothrombosis.


Subject(s)
Apolipoprotein B-100/metabolism , Blood Platelets/metabolism , Cell Communication , Cytokines/metabolism , Inflammation Mediators/metabolism , Inflammation/metabolism , Leukocytes/metabolism , Platelet Activation , Adenosine Diphosphate/metabolism , Adult , Apolipoprotein B-100/immunology , Blood Platelets/immunology , Cells, Cultured , Coculture Techniques , Cytokines/immunology , Human Umbilical Vein Endothelial Cells/immunology , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Immunity, Innate , Inflammation/blood , Inflammation/immunology , Inflammation Mediators/immunology , Leukocytes/immunology , Platelet Adhesiveness , Receptors, Purinergic P2Y12/metabolism , Signal Transduction , Thromboxane A2/metabolism , Time Factors , Young Adult
8.
Br J Cancer ; 109(3): 641-50, 2013 Aug 06.
Article in English | MEDLINE | ID: mdl-23846169

ABSTRACT

BACKGROUND: Circulating microRNAs (miRNAs) are emerging as promising biomarkers for prostate cancer. Here, we investigated the potential of these molecules to assist in prognosis and treatment decision-making. METHODS: MicroRNAs in the serum of patients who had experienced rapid biochemical recurrence (BCR) (n=8) or no recurrence (n=8) following radical prostatectomy (RP) were profiled using high-throughput qRT-PCR. Recurrence-associated miRNAs were subsequently quantitated by qRT-PCR in a validation cohort comprised of 70 patients with Gleason 7 cancers treated by RP, 31 of whom had undergone disease progression following surgery. The expression of recurrence-associated miRNAs was also examined in tumour tissue cohorts. RESULTS: Three miRNAs - miR-141, miR-146b-3p and miR-194 - were elevated in patients who subsequently experienced BCR in the screening study. MiR-146b-3p and miR-194 were also associated with disease progression in the validation cohort, as determined by log-rank tests and Cox proportional hazards regression. Multivariate analysis revealed that miR-146b-3p possessed prognostic information beyond standard clinicopathological parameters. Analysis of tissue cohorts revealed that miR-194 was robustly expressed in the prostate, elevated in metastases, and its expression in primary tumours was associated with a poor prognosis. CONCLUSION: Our study suggests that circulating miRNAs, measured at the time of RP, could be combined with current prognostic tools to predict future disease progression in men with intermediate risk prostate cancers.


Subject(s)
Biomarkers, Tumor/blood , MicroRNAs/blood , Prostatic Neoplasms/blood , Prostatic Neoplasms/genetics , Aged , Biomarkers, Tumor/genetics , Humans , Male , Neoplasm Recurrence, Local/blood , Neoplasm Recurrence, Local/genetics
9.
Oncogene ; 32(48): 5481-91, 2013 Nov 28.
Article in English | MEDLINE | ID: mdl-23708653

ABSTRACT

The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB)-axis is a critical modulator of cell cycle entry and is aberrant in many human cancers. New nodes of therapeutic intervention are needed that can delay or combat the onset of malignancies. The antitumor properties and mechanistic functions of PD-0332991 (PD; a potent and selective CDK4/6 inhibitor) were investigated using human prostate cancer (PCa) models and primary tumors. PD significantly impaired the capacity of PCa cells to proliferate by promoting a robust G1-arrest. Accordingly, key regulators of the G1-S cell cycle transition were modulated including G1 cyclins D, E and A. Subsequent investigation demonstrated the ability of PD to function in the presence of existing hormone-based regimens and to cooperate with ionizing radiation to further suppress cellular growth. Importantly, it was determined that PD is a critical mediator of PD action. The anti-proliferative impact of CDK4/6 inhibition was revealed through reduced proliferation and delayed growth using PCa cell xenografts. Finally, first-in-field effects of PD on proliferation were observed in primary human prostatectomy tumor tissue explants. This study shows that selective CDK4/6 inhibition, using PD either as a single-agent or in combination, hinders key proliferative pathways necessary for disease progression and that RB status is a critical prognostic determinant for therapeutic efficacy. Combined, these pre-clinical findings identify selective targeting of CDK4/6 as a bona fide therapeutic target in both early stage and advanced PCa and underscore the benefit of personalized medicine to enhance treatment response.


Subject(s)
Antineoplastic Agents/pharmacology , Molecular Targeted Therapy , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Protein Kinase Inhibitors/pharmacology , Receptors, Androgen/metabolism , Signal Transduction/drug effects , Animals , Antineoplastic Agents/therapeutic use , Cell Cycle/drug effects , Cell Cycle/radiation effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cyclin-Dependent Kinase 4/antagonists & inhibitors , Cyclin-Dependent Kinase 6/antagonists & inhibitors , Feasibility Studies , Humans , Male , Mice , Piperazines/pharmacology , Piperazines/therapeutic use , Prostatic Neoplasms/metabolism , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms, Castration-Resistant/metabolism , Prostatic Neoplasms, Castration-Resistant/pathology , Protein Kinase Inhibitors/therapeutic use , Pyridines/pharmacology , Pyridines/therapeutic use , Retinoblastoma/drug therapy , Retinoblastoma/pathology , Xenograft Model Antitumor Assays
10.
Cell Death Differ ; 20(8): 987-97, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23598363

ABSTRACT

Non-proliferating oocytes within avascular regions of the ovary are exquisitely susceptible to chemotherapy. Early menopause and sterility are unintended consequences of chemotherapy, and efforts to understand the oocyte apoptotic pathway may provide new targets for mitigating this outcome. Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin. However, the mechanism by which imatinib protects oocytes is not fully understood, and reports of the drug's efficacy have been contradictory. Using in vitro culture and subrenal grafting of mouse ovaries, we demonstrated that imatinib inhibits the cisplatin-induced apoptosis of oocytes within primordial follicles. We found that, before apoptosis, cisplatin induces c-Abl and TAp73 expression in the oocyte. Oocytes undergoing apoptosis showed downregulation of TAp63 and upregulation of Bax. While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death. Surprisingly, the conditional deletion of Trp63, but not ΔNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin. These data suggest that TAp63 is the master regulator of cisplatin-induced oocyte death. The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression. Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis. Thus, imatinib and other c-Abl kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.


Subject(s)
Antineoplastic Agents/adverse effects , Apoptosis/physiology , Cisplatin/adverse effects , Oocytes/physiology , Platinum/adverse effects , Signal Transduction/physiology , Tumor Suppressor Protein p53/antagonists & inhibitors , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Benzamides/pharmacology , Cells, Cultured , Cisplatin/pharmacology , DNA Damage/drug effects , DNA Damage/physiology , Dose-Response Relationship, Drug , Female , Imatinib Mesylate , In Vitro Techniques , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Models, Animal , Nuclear Proteins/drug effects , Nuclear Proteins/physiology , Oocytes/drug effects , Oogenesis/drug effects , Oogenesis/physiology , Piperazines/pharmacology , Platinum/pharmacology , Proto-Oncogene Proteins c-abl/antagonists & inhibitors , Proto-Oncogene Proteins c-abl/drug effects , Pyrimidines/pharmacology , Signal Transduction/drug effects , Tumor Suppressor Protein p53/drug effects , Tumor Suppressor Protein p53/physiology , bcl-2-Associated X Protein/drug effects , bcl-2-Associated X Protein/physiology
11.
J Virol ; 87(11): 6530-5, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23536673

ABSTRACT

Contradictory studies report either pro- or anti-inflammatory endothelial cell (EC) responses to human cytomegalovirus (hCMV) infection, hindering the validation of a potential link between this virus and associated inflammatory pathologies. Clarifying this issue, we report that hCMV induces a biphasic response. Early after inoculation, hCMV promoted lymphocyte and, to a lesser extent, neutrophil capture under in vivo relevant shear stresses. In contrast, later stages of infection rendered EC refractory to basal, or cytokine-induced, leukocyte recruitment.


Subject(s)
Cytomegalovirus Infections/immunology , Cytomegalovirus/physiology , Human Umbilical Vein Endothelial Cells/immunology , Cells, Cultured , Cytokines/immunology , Cytomegalovirus/immunology , Cytomegalovirus Infections/virology , Female , Human Umbilical Vein Endothelial Cells/virology , Humans , Leukocytes/immunology , Leukocytes/virology
12.
J Virol ; 86(13): 7158-66, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22532676

ABSTRACT

Endothelial cells (EC) can present antigen to either CD8(+) T lymphocytes through constitutively expressed major histocompatibility complex class I (MHC-I) or CD4(+) T lymphocytes through gamma interferon (IFN-γ)-induced MHC-II. Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma (KS), an EC neoplasm characterized by dysregulated angiogenesis and a substantial inflammatory infiltrate. KSHV is understood to have evolved strategies to inhibit MHC-I expression on EC and MHC-II expression on primary effusion lymphoma cells, but its effects on EC MHC-II expression are unknown. Here, we report that the KSHV infection of human primary EC inhibits IFN-γ-induced expression of the MHC-II molecule HLA-DR at the transcriptional level. The effect is functionally significant, since recognition by an HLA-DR-restricted CD4(+) T-cell clone in response to cognate antigen presented by KSHV-infected EC was attenuated. Inhibition of HLA-DR expression was also achieved by exposing EC to supernatant from KSHV-inoculated EC before IFN-γ treatment, revealing a role for soluble mediators. IFN-γ-induced phosphorylation of STAT-1 and transcription of CIITA were suppressed in KSHV-inoculated EC via a mechanism involving SOCS3 (suppressor of cytokine signaling 3). Thus, KSHV infection resulted in transcriptional upregulation of SOCS3, and treatment with RNA interference against SOCS3 relieved virus-induced inhibition of IFN-γ-induced STAT-1 phosphorylation. Since cell surface MHC-II molecules present peptide antigens to CD4(+) T lymphocytes that can function either as direct cytolytic effectors or to initiate and regulate adaptive immune responses, inhibition of this antigen-presenting pathway would provide a survival advantage to the virus.


Subject(s)
Endothelial Cells/immunology , HLA-DR Antigens/biosynthesis , Herpesvirus 8, Human/immunology , Host-Pathogen Interactions , Immune Tolerance , Nuclear Proteins/antagonists & inhibitors , Suppressor of Cytokine Signaling Proteins/metabolism , Trans-Activators/antagonists & inhibitors , Cells, Cultured , Down-Regulation , Endothelial Cells/virology , Herpesvirus 8, Human/pathogenicity , Humans , Suppressor of Cytokine Signaling 3 Protein , Transcription, Genetic
13.
Afr Health Sci ; 12(3): 249-58, 2012 Sep.
Article in English | MEDLINE | ID: mdl-23382737

ABSTRACT

BACKGROUND: Access to pediatric antiretroviral formulations is increasing in resource-limited countries, however adult FDCs are still commonly used by antiretroviral therapy (ART) programs. OBJECTIVE: To describe long-term effectiveness of using adult FDC of d4T+3TC+NVP (Triomune) in children for HIV treatment. METHODS: Clinical, immunologic, and virologic outcomes of HIV-infected ART-naïve children aged six months to 12 years, were evaluated up to 96 weeks post-ART initiation. RESULTS: From March 2004 to June 2006, 104 children were followed with a median age of 5.4 years, median CD4 cell percent and HIV-1 RNA were 11.0% (IQR 6.7-13.9) and 348,846copies/mL (IQR 160,941-681,313) respectively at baseline. Using Kaplan-Meir estimates, 75% of children had undetectable viral loads (<400copies/mL) at 96 weeks of ART. Children with a baseline CD4 cell percent >15% were 3 times more likely to achieve viral load <400copies/mL than those with baseline CD4 cell percent <5% after adjusting for baseline age {aHR = 3.03 (1.10-8.32), p=0.03}; no difference was found among those with CD4 cell percent >5-14.9% and <5%. CONCLUSION: Treatment with generic adult FDC for HIV-infected Ugandan children led to sustained clinical, immunologic and virologic response during 96 weeks of ART. Early initiation of ART is key to achieving virological success.


Subject(s)
Anti-HIV Agents/therapeutic use , Drugs, Generic/therapeutic use , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/drug effects , Lamivudine/therapeutic use , Nevirapine/therapeutic use , Stavudine/therapeutic use , Adult , Anti-HIV Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Body Weight , CD4 Lymphocyte Count , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , HIV Infections/immunology , Humans , Infant , Kaplan-Meier Estimate , Lamivudine/administration & dosage , Male , Medication Adherence , Nevirapine/administration & dosage , Stavudine/administration & dosage , Time Factors , Treatment Outcome , Viral Load/drug effects
14.
Endocrinology ; 152(10): 3728-37, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21846805

ABSTRACT

There is emerging evidence that androgens inhibit proliferation of normal and malignant breast epithelial cells, but the actions of androgens in normal mammary gland morphogenesis are not well understood. In this study, we investigated whether development of the murine mammary gland could be altered by stimulating or suppressing androgen receptor (AR) signaling in vivo. Intact virgin female mice aged 5 wk (midpuberty) or 12 wk (postpuberty) were implanted with slow-release pellets containing either placebo, 5α-dihydrotestosterone (1.5 mg) or the AR antagonist flutamide (60 mg). Treatment with 5α-dihydrotestosterone from midpuberty to 12 wk of age-retarded ductal extension by 40% (P = 0.007), but treatment from 12-21 wk had no significant effect on gland morphology. In contrast, inhibition of AR signaling with flutamide from midpuberty had no effect on the mammary gland, but flutamide treatment from 12-21 wk increased ductal branching (P = 0.004) and proliferation (P = 0.03) of breast epithelial cells. The increased proliferation in flutamide-treated mice was not correlated with serum estradiol levels or estrogen receptor-α (ERα) expression. In control mice, the frequency and intensity of AR immunostaining in mammary epithelial cells was significantly increased in the 12- to 21-wk treatment group compared with the 5- to 12-wk group (P < 0.001). In contrast, no change in ERα occurred, resulting in a marked increase in the AR to ERα ratio from 0.56 (±0.12) to 1.47 (±0.10). Our findings indicate that androgen signaling influences development and structure of the adult mammary gland and that homeostasis between estrogen and androgen signaling in mature glands is critical to constrain the proliferative effects of estradiol.


Subject(s)
Androgen Antagonists/pharmacology , Dihydrotestosterone/pharmacology , Flutamide/pharmacology , Mammary Glands, Animal/drug effects , Animals , Apoptosis/drug effects , Cell Proliferation/drug effects , Epithelial Cells/drug effects , Epithelial Cells/physiology , Estradiol/blood , Female , Mammary Glands, Animal/pathology , Mice , Mice, Inbred C57BL , Receptors, Androgen/analysis , Receptors, Estrogen/analysis , Sexual Maturation
15.
J Gen Virol ; 92(Pt 10): 2394-2398, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21697347

ABSTRACT

Kaposi's sarcoma-associated herpesvirus (KSHV) encodes four viral interferon regulatory factors (vIRF-1-4). We investigated the mechanism and consequences of vIRF-2-mediated inhibition of interferon-response element signalling following type I interferon (IFN) induction. Western blot and electrophoretic mobility-shift assays identified the interferon-stimulated gene factor-3 (ISGF-3) components STAT1 and IRF-9 as the proximal targets of vIRF-2 activity. The biological significance of vIRF-2 inhibition of ISGF-3 was demonstrated by vIRF-2-mediated rescue of the replication of the IFN-sensitive virus encephalomyocarditis virus. This study provides both a mechanism and evidence for KSHV vIRF-2-mediated suppression of the consequences of type 1 IFN-induced signalling.


Subject(s)
Herpesvirus 8, Human/immunology , Herpesvirus 8, Human/pathogenicity , Immune Evasion , Interferon Regulatory Factors/metabolism , Interferon Type I/antagonists & inhibitors , Interferon-Stimulated Gene Factor 3, gamma Subunit/antagonists & inhibitors , STAT1 Transcription Factor/antagonists & inhibitors , Viral Proteins/metabolism , Blotting, Western , Electrophoretic Mobility Shift Assay , Encephalomyocarditis virus/growth & development , Encephalomyocarditis virus/immunology , Virus Replication/immunology
16.
J Virol ; 85(14): 7321-32, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21543487

ABSTRACT

Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma (KS), an endothelial cell (EC) neoplasm characterized by dysregulated angiogenesis and inflammation. KSHV infection of EC causes production of proinflammatory mediators, regarded as possible initiators of the substantial mononuclear leukocyte recruitment seen in KS. Conversely, KSHV immune evasion strategies exist, such as degradation of EC leukocyte adhesion receptors by viral proteins. Here, we report the effects of KSHV infection of primary EC on recruitment of flowing leukocytes. Infection did not initiate adhesion of any leukocyte subset per se. However, on cytokine-stimulated EC, KSHV specifically inhibited neutrophil, but not PBL or monocyte, transmigration, an observation consistent with the inflammatory cell profile found in KS lesions in vivo. This inhibition could be recapitulated on uninfected EC using supernatant from infected cultures. These supernatants contained elevated levels of human interleukin 6 (hIL-6), and both the KSHV- and the supernatant-induced inhibitions of neutrophil transmigration were abrogated in the presence of a hIL-6 neutralizing antibody. Furthermore, preconditioning of EC with hIL-6 mimicked the effect of KSHV. Using RNA interference (RNAi), we show that upregulation of suppressor of cytokine signaling 3 (SOCS3) was necessary for this effect of hIL-6. These studies reveal a novel paracrine mode of KSHV immune evasion, resulting in reduced recruitment of neutrophils, a cell type whose antiviral and antitumor roles are becoming increasingly appreciated. Moreover, the findings have implications for our understanding of the contribution of hIL-6 to the pathogenesis of other inflammatory disorders and tumors in which this cytokine is abundant.


Subject(s)
Endothelium, Vascular/virology , Herpesvirus 6, Human/pathogenicity , Interleukin-6/physiology , Neutrophils/cytology , Sarcoma, Kaposi/virology , Tumor Escape , Blotting, Western , Cells, Cultured , Flow Cytometry , Herpesvirus 6, Human/immunology , Humans , Reverse Transcriptase Polymerase Chain Reaction
17.
Trop Med Int Health ; 15(4): 442-53, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20149165

ABSTRACT

OBJECTIVES: In sub-Saharan Africa, many viral infections, including Epstein-Barr virus, cytomegalovirus, Kaposi's sarcoma-associated herpesvirus and hepatitis B are acquired in childhood. While saliva is an important transmission conduit for these viruses, little is known about how saliva is passed to African children. We endeavoured to identify the range and determinants of acts by which African children are exposed to saliva. METHODS: To identify the range of acts by which African children are exposed to saliva, we conducted focus groups, semi-structured interviews and participant observations in an urban and a rural community in South Africa. To measure the prevalence and determinants of the identified acts, we administered a questionnaire to a population-based sample of caregivers. RESULTS: We identified 12 caregiving practices that expose a child's oral-respiratory mucosa, cutaneous surfaces or anal-rectal mucosa to saliva. Several acts were heretofore not described in the contemporary literature (e.g., caregiver inserting finger lubricated with saliva into child's rectum to relieve constipation). Among 896 participants in the population-based survey, many of the acts were commonly practised by all respondent types (mothers, fathers, grandmothers and siblings). The most common were premastication of food, sharing sweets and premastication of medicinal plants that are spit onto a child's body. CONCLUSIONS: African children are exposed to saliva through a variety of acts, practised by a variety of caregivers, with no single predominant practice. This diversity poses challenges for epidemiologic work seeking to identify specific saliva-passing practices that transmit viruses. Most acts could be replaced by other actions and are theoretically preventable.


Subject(s)
Child Care/methods , Infectious Disease Transmission, Vertical , Saliva/virology , Virus Diseases/transmission , Activities of Daily Living , Adolescent , Caregivers , Child , Child, Preschool , Cytomegalovirus Infections/transmission , Epstein-Barr Virus Infections/transmission , Female , Focus Groups , Hepatitis B/transmission , Herpesviridae Infections/transmission , Humans , Infant , Male , Rural Population , South Africa , Surveys and Questionnaires , Urban Population
18.
Br J Cancer ; 99(9): 1511-6, 2008 Nov 04.
Article in English | MEDLINE | ID: mdl-18813309

ABSTRACT

An influence of Western diet and lifestyle factors observed among Singapore Chinese may contribute to the population's marked rise in colorectal cancer incidence over the past two decades. Thus far, however, there is little evidence for individual nutrients and foods as major contributing factors in this population. We evaluated whether patterns of food intake were associated with colorectal cancer in a population-based cohort of 61,321 Singapore Chinese that was established in 1993-98. Two dietary patterns, meat-dim sum and vegetable-fruit-soy, were previously identified by principal components analysis using baseline dietary data from a validated 165-item food frequency questionnaire. As of 31 December 2005, 961 incident colorectal cancer cases were diagnosed. Proportional hazards regression was used to calculate adjusted hazard ratios. Using nearly 10 years of follow-up data, we observed no association with either the meat-dim sum or vegetable-fruit-soy pattern for colorectal cancer. In conclusion, neither individual nutrients or foods nor dietary patterns appear to explain the rise in colorectal cancer among Singapore Chinese population.


Subject(s)
Colorectal Neoplasms/etiology , Feeding Behavior , Aged , Asian People , Cohort Studies , Colorectal Neoplasms/epidemiology , Diabetes Mellitus, Type 2/complications , Female , Humans , Male , Middle Aged , Principal Component Analysis , Prospective Studies , Singapore/epidemiology
19.
Am J Epidemiol ; 157(5): 434-45, 2003 Mar 01.
Article in English | MEDLINE | ID: mdl-12615608

ABSTRACT

The authors examined the association between colon cancer and meat intake categorized by level of doneness, cooking method, and estimated levels of heterocyclic amines (HCAs), benzo[a]pyrene, and mutagenicity. Data were collected as part of a population-based, case-control study of colon cancer in North Carolina between 1996 and 2000 that included 701 African-American (274 cases, 427 controls) and 957 White (346 cases, 611 controls) participants. Odds ratios were calculated by using unconditional logistic regression, comparing the fifth to the first quintile levels of intake or exposure. Intake of red meat was positively associated with colon cancer (odds ratio (OR) = 2.0, 95% confidence interval (CI): 1.3, 3.2). Associations with meat intake by cooking method were strongest for pan-fried red meat (OR = 2.0, 95% CI: 1.4, 3.0). Associations with meat intake by doneness were strongest for well-/very well done red meat (OR = 1.7, 95% CI: 1.2, 2.5). The strongest association for individual HCAs was reported for 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (DiMeIQx) across all levels of exposure, with odds ratios of 1.8-2.0. Overall, sophisticated exposure measures were used to report modest, positive associations between red meat intake and colon cancer consistent with the hypothesis that HCAs may be among the etiologically relevant compounds in red meat.


Subject(s)
Amines/adverse effects , Colonic Neoplasms/etiology , Eating , Heterocyclic Compounds/adverse effects , Meat/adverse effects , Adult , Black or African American/statistics & numerical data , Aged , Aged, 80 and over , Case-Control Studies , Colonic Neoplasms/epidemiology , Cooking , Female , Humans , Logistic Models , Male , Middle Aged , North Carolina/epidemiology , Surveys and Questionnaires , White People/statistics & numerical data
20.
Anticancer Res ; 21(4A): 2809-14, 2001.
Article in English | MEDLINE | ID: mdl-11724359

ABSTRACT

BACKGROUND: Aberrant bcl-2 expression frequently occurs in colorectal carcinoma. The current study investigated if CpG sites in bcl-2 were methylated in colorectal carcinoma and if methylation correlated with loss of expression of bcl-2 mRNA. METHODS: Methylation was assessed in 23 matched normal mucosae and colonic carcinomas by Southern blotting with methylation-sensitive enzymes. Expression of bcl-2 mRNA was assessed by Northern blotting. RESULTS: A SacII site in exon 2 of the bcl-2 gene was methylated in 5 carcinomas, plus an adjacent HpaII sites in 1 tumour. SacII site in the bcl-2 promoter were not methylated. Elevated levels of bcl-2 mRNA were detected in 3 carcinomas, 5 showed decreased expression and 4 were unchanged. CONCLUSIONS: De novo methylation of CpG sites in exon 2 of the bcl-2 gene occurs during the development of colorectal carcinoma. However, there was no relationship between expression of bc1-2 mRNA and methylation of specific CpG sites.


Subject(s)
Colorectal Neoplasms/genetics , CpG Islands , DNA Methylation , Genes, bcl-2/genetics , Blotting, Northern , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , DNA-Cytosine Methylases/metabolism , Deoxyribonucleases, Type II Site-Specific/metabolism , Exons , Gene Expression Regulation, Neoplastic , Humans , Neoplasm Staging , Promoter Regions, Genetic , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins c-bcl-2/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...